FIELD: medicine.
SUBSTANCE: group of inventions relates to an oral pharmaceutical composition for use in the treatment of childhood epilepsy, containing cannabidiol (CBD) in an amount of approximately 10 to 30% by weight based on the total composition, poloxamer 124 and poloxamer 188, where the total amount of poloxamer is about 30 to 60% by weight based on the total composition and diacetin in the amount of about 20 to 30% by weight based on the total composition and, where the composition is substantially free of oil, also refers to a method of treating a patient with a disease or disorder selected from the group consisting of Dravet syndrome, Lennox-Gastaut syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms and tuberous sclerosis complex, also refers to a method of treatment patient with atonic, small epileptic or partial seizures, in particular simple or complex seizures, also refers to the use of a pharmaceutical composition in the manufacture of a medicament for the treatment of a disease or disorder selected from the group, Dravet syndrome, Lennox-Gastaut syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, juvenile spasms , West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, and also relates to the use of a pharmaceutical composition in the manufacture of a medicament for the treatment of atonic, petit mal or partial seizures, in particular simple or complex seizures.
EFFECT: group of inventions ensures the achievement of improved bioavailability of the composition.
15 cl, 1 dwg, 7 tbl
